- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | 2.532 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| 11.08. | Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum | 2 | Benzinga.com | ||
| 11.08. | Stifel raises Alamar Biosciences stock price target on earnings beat | 1 | Investing.com | ||
| 11.08. | Alamar outlines $116M-$120M 2026 revenue outlook while targeting 100+ instruments and $400,000+ pull-through | 1 | Seeking Alpha | ||
| 10.08. | Alamar Q2 2026 slides: consumables surge 147%, margin hits 60% | 1 | Investing.com | ||
| 10.08. | Alamar Biosciences: Starkes Umsatzwachstum und Rekordmarge bei anhaltenden Verlusten | 4 | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences expands proteomics partnership by 86,000 samples | 3 | Investing.com | ||
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 10.08. | Alamar Biosciences erweitert Proteomik-Partnerschaft um 86.000 Proben | - | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 10.08. | Alamar Biosciences, Inc.: Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures | 3 | GlobeNewswire (USA) | ||
| 28.07. | Alamar Biosciences launches immune profiling panel for research | 1 | Investing.com | ||
| 28.07. | Alamar Biosciences stellt neues Panel zur Immunprofilierung für die Forschung vor | 2 | Investing.com Deutsch | ||
| 28.07. | Alamar Biosciences, Inc.: Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome | 452 | GlobeNewswire (Europe) | Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
Highly sensitive... ► Artikel lesen | |
| 27.07. | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | Small- & Micro Cap Investment | |||
| 15.07. | Alamar Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | Health Wave Partners Acquires Alamar Senior Living | 1 | pulse2.com | ||
| 14.07. | Alamar Biosciences, Inc.: Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 | 1 | GlobeNewswire (USA) | ||
| 13.07. | Alamar Biosciences, Inc.: Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases | 510 | GlobeNewswire (Europe) | National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq Neuro 220 panel.
Resulting... ► Artikel lesen | |
| 10.07. | Alamar's platform to feature in 140+ presentations at AAIC | 1 | Investing.com | ||
| 10.07. | Über 140 Präsentationen: Alamar-Plattform im Fokus der internationalen Alzheimer-Konferenz | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 33,640 | -0,09 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,740 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,900 | 0,00 % | Dyne Therapeutics auf Morgan Stanley Konferenz: Pläne zur Markteinführung im Fokus | ||
| PRAXIS PRECISION MEDICINES | 312,90 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CG ONCOLOGY | 72,55 | 0,00 % | CG Oncology auf Morgan Stanley Konferenz: Pläne für Markteinführung, Daten und Skalierung | ||
| RELAY THERAPEUTICS | 18,970 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 33,150 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,910 | 0,00 % | Mineralys auf Wells Fargo Konferenz: Markteinführung von Lorundrostat nimmt Gestalt an | ||
| SUMMIT THERAPEUTICS | 17,405 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| EDGEWISE THERAPEUTICS | 43,630 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,430 | 0,00 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ERASCA | 16,265 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 20,540 | 0,00 % | BTIG hebt Kursziel für Cullinan Oncology nach Studiendaten an | ||
| VIR BIOTECHNOLOGY | 10,440 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,540 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
ALAMAR BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 28,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.